These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 29859917)

  • 1. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
    Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
    Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial.
    Devanand DP; Crocco E; Forester BP; Husain MM; Lee S; Vahia IV; Andrews H; Simon-Pearson L; Imran N; Luca L; Huey ED; Deliyannides DA; Pelton GH
    Am J Geriatr Psychiatry; 2022 Jan; 30(1):32-42. PubMed ID: 34059401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
    J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.
    Ballard CG; Coate B; Abler V; Stankovic S; Foff E
    Int J Geriatr Psychiatry; 2020 Nov; 35(11):1402-1408. PubMed ID: 32729631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.
    Herrmann N; Gauthier S; Boneva N; Lemming OM;
    Int Psychogeriatr; 2013 Jun; 25(6):919-27. PubMed ID: 23472619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
    Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; Lyketsos CG;
    Int Psychogeriatr; 2015 Dec; 27(12):2059-67. PubMed ID: 26305876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
    Wilcock GK; Ballard CG; Cooper JA; Loft H
    J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
    JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.
    Devanand DP; Pelton GH; Cunqueiro K; Sackeim HA; Marder K
    Int J Geriatr Psychiatry; 2011 Sep; 26(9):937-43. PubMed ID: 21845596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
    Tariot PN; Schneider L; Katz IR; Mintzer JE; Street J; Copenhaver M; Williams-Hughes C
    Am J Geriatr Psychiatry; 2006 Sep; 14(9):767-76. PubMed ID: 16905684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses.
    Nirogi R; Jayarajan P; Benade V; Shinde A; Goyal VK; Jetta S; Ravula J; Abraham R; Grandhi VR; Subramanian R; Pandey SK; Badange RK; Mohammed AR; Jasti V; Ballard C; Cummings J
    Int J Geriatr Psychiatry; 2022 Oct; 37(10):. PubMed ID: 36168659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine.
    Buckley PF; Paulsson B; Brecher M
    J Affect Disord; 2007; 100 Suppl 1():S33-43. PubMed ID: 17376537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease.
    Herrmann N; Ruthirakuhan M; Gallagher D; Verhoeff NPLG; Kiss A; Black SE; Lanctôt KL
    Am J Geriatr Psychiatry; 2019 Nov; 27(11):1161-1173. PubMed ID: 31182351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression.
    Wang LY; Shofer JB; Rohde K; Hart KL; Hoff DJ; McFall YH; Raskind MA; Peskind ER
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):744-51. PubMed ID: 19700947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
    Clark WS; Street JS; Feldman PD; Breier A
    J Clin Psychiatry; 2001 Jan; 62(1):34-40. PubMed ID: 11235926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.
    Herrmann N; Cappell J; Eryavec GM; Lanctôt KL
    CNS Drugs; 2011 May; 25(5):425-33. PubMed ID: 21476613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort Study: Methods, Baseline and Longitudinal Results of the A3C Study.
    De Mauleon A; Delrieu J; Cantet C; Vellas B; Andrieu S; Rosenberg PB; Lyketsos CG; Soto Martin M
    J Prev Alzheimers Dis; 2021; 8(2):199-209. PubMed ID: 33569568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.